Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Prathibha Surapaneni, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2204.

https://doi.org/10.1182/blood-2019-129442

Published: 2019

Journal Articles

Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Experience

Juan F Garza, MD, Michelle Janania Martinez, MD, Prathibha Surapaneni, MD, Tyler W Snedden, MD, Snegha Ananth, MBBS, David J Gregorio, DO, Sushanth Kakarla, MD, Jeremy Rawlings, MD, Joel E Michalek, PhD, Qianqian Liu, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 2141.

https://doi.org/10.1182/blood-2019-129085

Published: 2019

Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Experience in a Majority-Minority Community: The UT Health San Antonio Story

Daniela Hernandez, MD, Michelle Janania Martinez, MD, Juan F Garza, MD, Tyler W Snedden, MD, Adolfo E Diaz, MD

Blood (2019) 134 (Supplement_1): 2916.

https://doi.org/10.1182/blood-2019-127485

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Christopher R Frei, Hannah Le, PharmD, MPH, Daniel McHugh, Cynthia Elesinmogun, PharmD, Samantha Galley, Kathleen Franklin, Juan Tavera, Michelle Janania Martinez, MD, David J Gregorio, DO, Snegha Ananth, MBBS, Ricardo Uribe, Prathibha Surapaneni, Manuel Ricardo Espinoza-Gutarra, MD, Michael Song, Xavier Jones, Chengwen Teng, Obiageri O Obodozie-Ofoegbu, Zohra Nooruddin, MD

Blood (2019) 134 (Supplement_1): 795.

https://doi.org/10.1182/blood-2019-122434

Published: 2019

Journal Articles

Hodgkin Lymphoma Outcomes: Can We Expect Ethnic Parity in a Hispanic Prevalent Population?

Michelle Janania Martinez, MD, Prathibha Surapaneni, MD, Juan F Garza, MD, Tyler W Snedden, MD, Snegha Ananth, MBBS, Jeremy Rawlings, MD, David J Gregorio, DO, Sushanth Kakarla, MD, Qianqian Liu, PhD, Joel E Michalek, PhD, Adolfo Enrique Diaz, MD

Blood (2019) 134 (Supplement_1): 4056.

https://doi.org/10.1182/blood-2019-129058

Published: 2019

Journal Articles

Veterans Treated with R-CHOP for Diffuse Large B Cell Lymphoma Compared to Neighboring Hospital: An Interesting Discovery for Treatment Outcomes

Jessica Trevino Jones, MD, Manuel Ricardo Espinoza-Gutarra, MD, Sushanth Kakarla, MBBS, Michelle Janania Martinez, MD, David Gregorio, MD, Prathibha Surapaneni, Michael Mader, Zohra Nooruddin, MD

Blood (2018) 132 (Supplement 1): 3604.

https://doi.org/10.1182/blood-2018-99-119667

Published: 2018

Journal Articles

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

Michelle Janania Martinez, MD, Adolfo E Diaz, MD, Cynthia Forker, MD

Blood (2018) 132 (Supplement 1): 5423.

https://doi.org/10.1182/blood-2018-99-119865

Published: 2018

Journal Articles

A Look at Lymphoid Neoplasms in Patients over 65: Are We Less Aggressive - and Does It Affect Outcome?

Jessica Trevino Jones, MD, Sushanth Kakarla, MBBS, Annie Hung, MD, Michelle Janania Martinez, MD, Prathibha Surapaneni, Juan Garza, MD, David Gregorio, MD, Elva Nora Osuna Salazar, MD, Joel E Michalek, PhD, Qianqian Liu, MS, Adolfo E Diaz, MD

Blood (2018) 132 (Supplement 1): 5910.

https://doi.org/10.1182/blood-2018-99-119584

Published: 2018

Journal Articles

Payment Plans Bridging Gap: An Equalizer for the Hispanic Population with Lymphoid Neoplasms in a Majority-Minority Community

Blood (2018) 132 (Supplement 1): 2303.

https://doi.org/10.1182/blood-2018-99-115184

Published: 2018

Journal Articles

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Elizabeth Bowhay-Carnes, MD, Christos Fountzilas, MD, Michelle Janania Martinez, MD, Brandon Konkel, MD, Brandon Stormes, Anand Karnad, MD

Blood (2015) 126 (23): 5092.

https://doi.org/10.1182/blood.V126.23.5092.5092

Published: 2015

NARROW

Impact of Co-Morbidities on Outcome in a Predominantly Hispanic Population of Hodgkin and Non-Hodgkin Lymphoma Patients

Does Insurance Status Interfere with Outcomes in Patients with Hodgkin and Non-Hodgkin Lymphoma?: The UT Health San Antonio Experience

Diffuse Large B Cell Lymphoma (DLBCL) Experience in a Majority-Minority Community: The UT Health San Antonio Story

Treatment Patterns and Outcomes of 1205 Patients on Novel Agents in the US Veterans Health Administration (VHA) System: Results from the Largest Retrospective EMR and Chart Review Study in the Real-World Setting

Hodgkin Lymphoma Outcomes: Can We Expect Ethnic Parity in a Hispanic Prevalent Population?

Veterans Treated with R-CHOP for Diffuse Large B Cell Lymphoma Compared to Neighboring Hospital: An Interesting Discovery for Treatment Outcomes

HIV-Related Primary Diffuse Large B Cell Lymphoma of the Appendix. What Can We Learn?

A Look at Lymphoid Neoplasms in Patients over 65: Are We Less Aggressive - and Does It Affect Outcome?

Payment Plans Bridging Gap: An Equalizer for the Hispanic Population with Lymphoid Neoplasms in a Majority-Minority Community

Chemotherapy Relative Dose Intensity and Therapy Efficacy in Hodgkin and Non-Hodgkin Lymphoma: The Effect of Dose Reductions and Delays on Cure

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only